{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:04:07Z","timestamp":1790841847261,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few recent studies from registries have reported an improvement in overall survival of younger patients with acute myeloid leukemia (AML). However, reasons for this improvement are not defined. We analyzed the therapeutic course and outcome of 976 patients treated by intensive chemotherapy between 2000 and 2014. The number of patients receiving allogeneic stem cell transplantation in first or second response significantly increased over time whereas autologous transplantation was progressively abandoned. In the 513 younger patients, there were no differences in first complete response, induction failure, incidence of relapse, or non-relapse mortality over time. The period of time was significantly associated with a better overall survival especially in 2010\u20132014. The 2010\u20132014 period effect was still significant in multivariate analysis and was independent of allogeneic stem cell transplantation. In the 463 older patients, there was a significant interaction between the period and leukocytosis in multivariate analysis meaning that the 2010\u20132014 period had only an impact in patients with white blood cell count &gt;50\u2009giga\/L for response and overall survival. Progresses have been made in each phase of the therapeutic course of younger AML patients resulting in survival improvement. In older patients, the outcome of hyperleukocytic patients has significantly improved in 2010\u20132014.<\/jats:p>","DOI":"10.1038\/s41408-017-0011-1","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T16:08:26Z","timestamp":1511453306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Improved outcome for AML patients over the years 2000\u20132014"],"prefix":"10.1038","volume":"7","author":[{"given":"Sarah","family":"Bertoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Borel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Guenounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Luquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Delabesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","unstructured":"DeAngelo D. J., Stein E. M. & Ravandi F. Evolving therapies in acute myeloid leukemia: progress at last?Am. Soc. Clin. Oncol. Educ. Book \n                           35, e302\u2013e312 (2016).","DOI":"10.1200\/EDBK_161258"},{"key":"11_CR2","doi-asserted-by":"crossref","unstructured":"Sekeres M. A. & Steensma D. P. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J. Clin. Oncol. \n                           30, 4061\u20134063 (2012).","DOI":"10.1200\/JCO.2012.44.2962"},{"key":"11_CR3","doi-asserted-by":"crossref","unstructured":"Dohner H., Weisdorf D. J. & Bloomfield C. D. Acute myeloid leukemia. N. Engl. J. Med. \n                           373, 1136\u20131152 (2015).","DOI":"10.1056\/NEJMra1406184"},{"key":"11_CR4","first-page":"19","volume":"27","author":"LF Ellison","year":"2016","unstructured":"Ellison, L. F. Increasing survival from leukemia among adolescents and adults in Canada: a closer look. Health Rep. \n                           27, 19\u201326 (2016).","journal-title":"Health Rep."},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant, M. et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. \n                           15, 931\u2013942 (2014).","journal-title":"Lancet Oncol."},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein, M. S., Ershler, W. B., Jemal, A., Yates, J. W. & Baer, M. R. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer \n                           119, 2720\u20132727 (2013).","journal-title":"Cancer"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1182\/blood-2008-09-179341","volume":"113","author":"AR Derolf","year":"2009","unstructured":"Derolf, A. R. et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood \n                           113, 3666\u20133672 (2009).","journal-title":"Blood"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3324\/haematol.12304","volume":"93","author":"D Pulte","year":"2008","unstructured":"Pulte, D., Gondos, A. & Brenner, H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica \n                           93, 594\u2013600 (2008).","journal-title":"Haematologica"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood \n                           116, 354\u2013365 (2010).","journal-title":"Blood"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.18632\/oncotarget.347","volume":"2","author":"O LaRochelle","year":"2011","unstructured":"LaRochelle, O. et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget \n                           2, 850\u2013861 (2011).","journal-title":"Oncotarget"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.2016.70.4551","volume":"35","author":"X Thomas","year":"2017","unstructured":"Thomas, X. et al. Randomized phase II study of clofarabine-based consolidation for younger adults with acute myeloid leukemia in first remission. J. Clin. Oncol. \n                           35, 1223\u20131230 (2017).","journal-title":"J. Clin. Oncol."},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2016.67.6213","volume":"35","author":"A Pigneux","year":"2017","unstructured":"Pigneux, A. et al. Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J. Clin. Oncol. \n                           35, 387\u2013393 (2017).","journal-title":"J. Clin. Oncol."},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/leu.2013.290","volume":"28","author":"C Recher","year":"2014","unstructured":"Recher, C. et al. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia. Leukemia \n                           28, 440\u2013443 (2014).","journal-title":"Leukemia"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan, E. et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood \n                           121, 2213\u20132223 (2013).","journal-title":"Blood"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2011-05-352989","volume":"119","author":"B Lioure","year":"2012","unstructured":"Lioure, B. et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood \n                           119, 2943\u20132948 (2012).","journal-title":"Blood"},{"key":"11_CR16","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2009.26.4648","volume":"28","author":"A Pigneux","year":"2010","unstructured":"Pigneux, A. et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J. Clin. Oncol. \n                           28, 3028\u20133034 (2010).","journal-title":"J. Clin. Oncol."},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood \n                           115, 453\u2013474 (2010).","journal-title":"Blood"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo, A. et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. \n                           15, 1628\u20131633 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/leu.2010.111","volume":"24","author":"P Chevallier","year":"2010","unstructured":"Chevallier, P. et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia \n                           24, 1380\u20131385 (2010).","journal-title":"Leukemia"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"J Fine","year":"1999","unstructured":"Fine, J. & G, R. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. \n                           94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"E244","DOI":"10.1002\/ajh.23848","volume":"89","author":"P Bories","year":"2014","unstructured":"Bories, P. et al. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. Am. J. Hematol. \n                           89, E244\u2013E252 (2014).","journal-title":"Am. J. Hematol."},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2009.012633","volume":"95","author":"A Chabrol","year":"2010","unstructured":"Chabrol, A. et al. Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica \n                           95, 996\u20131003 (2010).","journal-title":"Haematologica"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. \n                           356, 348\u2013359 (2007).","journal-title":"N. Engl. J. Med."},{"key":"11_CR24","volume":"128","author":"SB Christian R\u00e9cher","year":"2016","unstructured":"Christian R\u00e9cher, S. B. et al. Dexamethasone reduces incidence of relapse and improves overall survival in Hyperleucocytic acute myeloid leukemia. Blood \n                           128, 1636 (2016).","journal-title":"Blood"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk, R. F. et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. \n                           358, 1909\u20131918 (2008).","journal-title":"N. Engl. J. Med."},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","volume":"109","author":"JJ Cornelissen","year":"2007","unstructured":"Cornelissen, J. J. et al. Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood \n                           109, 3658\u20133666 (2007).","journal-title":"Blood"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth, J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA \n                           301, 2349\u20132361 (2009).","journal-title":"JAMA"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. \n                           361, 1249\u20131259 (2009).","journal-title":"N. Engl. J. Med."},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","volume":"31","author":"M Schaich","year":"2013","unstructured":"Schaich, M. et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J. Clin. Oncol. \n                           31, 2094\u20132102 (2013).","journal-title":"J. Clin. Oncol."},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1002\/ajh.23884","volume":"90","author":"R Devillier","year":"2015","unstructured":"Devillier, R. et al. Comparison of 60 or 90 mg\/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. Am. J. Hematol. \n                           90, E29\u2013E30 (2015).","journal-title":"Am. J. Hematol."},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett, A. K. et al. A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood \n                           125, 3878\u20133885 (2015).","journal-title":"Blood"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood \n                           129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","volume":"121","author":"B Lowenberg","year":"2013","unstructured":"Lowenberg, B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood \n                           121, 26\u201328 (2013).","journal-title":"Blood"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett, A. K. et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J. Clin. Oncol. \n                           31, 3360\u20133368 (2013).","journal-title":"J. Clin. Oncol."},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/mmy\/myw114","volume":"55","author":"G Dragonetti","year":"2017","unstructured":"Dragonetti, G., Criscuolo, M., Fianchi, L. & Pagano, L. Invasive aspergillosis in acute myeloid leukemia: are we making progress in reducing mortality? Med. Mycol. \n                           55, 82\u201386 (2017).","journal-title":"Med. Mycol."},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","volume":"97","author":"A Stucki","year":"2001","unstructured":"Stucki, A., Rivier, A. S., Gikic, M., Monai, N., Schapira, M. & Spertini, O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood \n                           97, 2121\u20132129 (2001).","journal-title":"Blood"},{"key":"11_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep36199","volume":"6","author":"M Kurata","year":"2016","unstructured":"Kurata, M. et al. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci. Rep. \n                           6, 36199 (2016).","journal-title":"Sci. Rep."},{"key":"11_CR38","doi-asserted-by":"crossref","unstructured":"Malani D. et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia \n                           31, 1187\u20131195 (2016).","DOI":"10.1038\/leu.2016.314"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOH.0000000000000212","volume":"23","author":"T Zuckerman","year":"2016","unstructured":"Zuckerman, T., Beyar-Katz, O. & Rowe, J. M. Should autotransplantation in acute myeloid leukemia in first complete remission be revisited? Curr. Opin. Hematol. \n                           23, 88\u201394 (2016).","journal-title":"Curr. Opin. Hematol."},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2015.179","volume":"50","author":"NC Gorin","year":"2015","unstructured":"Gorin, N. C. et al. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplant. \n                           50, 1495\u20131502 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","volume":"121","author":"S Bertoli","year":"2013","unstructured":"Bertoli, S. et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood \n                           121, 2618\u20132626 (2013).","journal-title":"Blood"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","volume":"127","author":"EM Stein","year":"2016","unstructured":"Stein, E. M. & Tallman, M. S. Emerging therapeutic drugs for AML. Blood \n                           127, 71\u201378 (2016).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0011-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0011-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0011-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:31:27Z","timestamp":1671730287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0011-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1038\/s41408-017-0011-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,29]]},"assertion":[{"value":"4 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"635"}}